Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
DNA Ginkgo Bioworks Holdings, Inc.
With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback